Mission Therapeutics has begun a 36-patient Phase 1b study of MTX325, a drug aimed at clearing out damaged mitochondria in ...
The Boston company says the deal more than doubles its patient reach and opens a path to brain-based sleep testing in primary ...
After 12 weeks, members of Omada’s GLP-1 Care Track had lost more weight and shifted their body makeup more than people on ...
Organoids are full of cells that shouldn’t be there, and sorting them out wrecks the vasculature. SynBITE prunes in place ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results